Live Breaking News & Updates on Refractory Medulloblastoma

Stay updated with breaking news from Refractory medulloblastoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion NV Business and Financial Update – FY 2020


 
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
 
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
 
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
 
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021.  The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,

Oxurion NV Business and Financial Update – FY 2020


 
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
 
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
 
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
 
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021.  The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,